Selinexor Patent Expiration
Selinexor is Used for treating relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Multiple Myeloma in adults. It was first introduced by Karyopharm Therapeutics Inc
Selinexor Patents
Given below is the list of patents protecting Selinexor, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xpovio | US10519139 | Polymorphs of Selinexor | Aug 14, 2035 | Karyopharm Theraps |
| Xpovio | US11746102 | Polymorphs of selinexor | Aug 14, 2035 | Karyopharm Theraps |
| Xpovio | US11753401 | Polymorphs of Selinexor | Aug 14, 2035 | Karyopharm Theraps |
| Xpovio | US11807629 | Polymorphs of Selinexor | Aug 14, 2035 | Karyopharm Theraps |
| Xpovio | US8999996 | Hydrazide containing nuclear transport modulators and uses thereof | Jul 03, 2033 | Karyopharm Theraps |
| Xpovio | US10544108 | Hydrazide containing nuclear transport modulators and uses thereof | Jul 26, 2032 | Karyopharm Theraps |
| Xpovio | US11034660 | Hydrazide containing nuclear transport modulators and uses thereof | Jul 26, 2032 | Karyopharm Theraps |
| Xpovio | US11787771 | Hydrazide containing nuclear transport modulators and uses thereof | Jul 26, 2032 | Karyopharm Theraps |
| Xpovio | US9079865 | Hydrazide containing nuclear transport modulators and uses thereof | Jul 26, 2032 | Karyopharm Theraps |
| Xpovio | US9714226 | Hydrazide containing nuclear transport modulators and uses thereof | Jul 26, 2032 | Karyopharm Theraps |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Selinexor's patents.
Latest Legal Activities on Selinexor's Patents
Given below is the list recent legal activities going on the following patents of Selinexor.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eGrant Notification | 07 Nov, 2023 | US11807629 |
| Mail Patent eGrant Notification | 07 Nov, 2023 | US11807629 |
| Recordation of Patent Grant Mailed Critical | 07 Nov, 2023 | US11807629 |
| Recordation of Patent eGrant | 07 Nov, 2023 | US11807629 |
| Email Notification Critical | 07 Nov, 2023 | US11807629 |
| Patent Issue Date Used in PTA Calculation Critical | 07 Nov, 2023 | US11807629 |
| Email Notification Critical | 19 Oct, 2023 | US11807629 |
| Issue Notification Mailed Critical | 18 Oct, 2023 | US11807629 |
| Email Notification Critical | 17 Oct, 2023 | US11787771 |
| Patent Issue Date Used in PTA Calculation Critical | 17 Oct, 2023 | US11787771 |
Selinexor's Family Patents
